daewoong jeuveau botulinum toxin

Bio & Pharma Daewoong wins permission for Nabota in Argentina

South Korea's Daewoong Pharmaceutical Co. announced on Monday that its botulinum toxin Nabota received product approval from Argentina's National Ad...

Bio & Pharma Daewoong, Indonesia's IPB to co-research on primate

South Korea's Daewoong Pharmaceutical Co. announced on Thursday that it signed a contract with Indonesia's Bogor Agricultural University (Institut P...

Bio & Pharma Medytox to supply $73 mn botulinum toxin to Brazilian firm

South Korea's biopharmaceutical firm Medytox Inc. announced on Tuesday that it signed a contract with Brazilian pharmaceutical company Blau Farmaceu...

Bio & Pharma Daewoong Pharmaceutical digitizes DB of 800 mn chemical compounds

South Korea's Daewoong Pharmaceutical announced on Monday that it has established a drug development system Daewoong AI System (DAISY) which combine...

Bio & Pharma Daewoong gets stem cell facility license in Indonesia

South Korea's Daewoong Pharmaceutical announced on Tuesday that its subsidiary Daewoong Biologics Indonesia has obtained a stem cell Lab Operational...

Bio & Pharma Daewoong exports $92.4 mn Depot injection tech to UAE

South Korea's Daewoong Pharmaceutical announced on Monday that it exported its technology for clinical development and commercialization rights of i...

Bio & Pharma Daewoong Pharm set to export Envlo Tab to Russia, CIS

Daewoong Pharmaceutical, a leading South Korean pharmaceutical company will export its new diabetes drug Envlo Tab. (active ingredient:enavogliflozi...

Bio & Pharma Daewoong Pharma, Merck team up for AI tech for new drug

South Korea's Daewoong Pharmaceutical announced on Tuesday it signed with memorandum of understanding (MOU) with Merck Life Science to build an arti...

Bio & Pharma Medytox to enter China’s botulinum toxin market with Newlux

South Korean pharmaceutical company Medytox Inc. on Tuesday announced its plan to enter the Chinese market for botulinum toxins (BTX) with its cut...

Bio & Pharma Daewoong Pharma's GER drug gets product OK from Mexico

South Korea’s Daewoong Pharmaceutical on Wednesday said its gastroesophageal reflux (GER) disease drug Fexuclue (active ingredient fexuprazan ...

Bio & Pharma Daewoong to develop eye drops for diabetic retinopathy

South Korea's Daewoong Pharmaceutical is venturing into the development of a product that can easily treat diabetic retinopathy in the form of ...

Bio & Pharma Daewoong gets patent of Nabota as migraine drug in US

South Korea's Daewoong Pharmaceutical Co. announced on Thursday that it has received a patent from the US Patent and Trademark Office for the use of...

Bio & Pharma Hugel resubmits application to FDA for botulinum toxin product

South Korea's biopharmaceutical company Hugel Inc., announced on Friday that it has resubmitted applications to the US Food and Drug Administration ...

Bio & Pharma Daewoong applies for approval of Envlo in Saudi Arabia

South Korea's Daewoong Pharmaceutical Co. announced on Friday that it has submitted an application for regulatory approval of its new diabetes treat...

Bio & Pharma Daewoong launches GERD treatment Fexuclu in Philippines

South Korea's Daewoong Pharmaceutical announced on Tuesday that it has launched the GERD treatment drug "Fexuclue" (active ingredient: Fexuprazan) i...

Bio & Pharma Daewoong's Nabota exceeds 600,000 customers in US

South Korea's Daewoong Pharmaceutical said on Thursday that its local loyalty program for Nabota (American name: Jeuveau) in the US, a botulinum tox...

Bio & Pharma HanAll, Daewoong to develop Parkinson's treatment with US partner

South Korea's HanAll Biopharma Co. and Daewoong Pharmaceutical on Thursday said they concluded a contract with NurrOn Pharmaceuticals of the US on...

Bio & Pharma Daewoong Pharmaceutical’s cumulative tech exports exceed $870 mn

South Korea’s Daewoong Pharmaceutical said on Friday that it had concluded three technology export agreements for new drugs and new drug candi...

Bio & Pharma Daewoong Pharma to build third botulinum toxin plant for $746 mn

South Korea’s Daewoong Pharmaceutical next year will open a third plant to greatly expand annual output of its botulinum toxin Nabota at a cos...

Bio & Pharma Daewoong to transfer techs for autoimmune disease to US pharma

South Korea's Daewoong Pharmaceutical announced on Friday that it has signed a technology export contract for the clinical development and commercia...

Beauty & Cosmetics Botulinum toxin resistance emerges as key factor for safe use

As demand for botulinum toxin for aesthetic purposes is globally increasing, safe use of the drug has emerged as one of the most important issues in...

Bio & Pharma Daewoong Pharma, UK firm to jointly develop autoimmune disease drug

South Korean drugmaker Daewoong Pharmaceutical Co. said on Tuesday that it has signed a cooperation agreement with Sygnature Discovery, a British ne...

Bio & Pharma Daewoong wins approval for GERD treatment Fexuclu in Chile

South Korean pharmaceutical company Daewoong Pharmaceutical announced on Tuesday that it has received marketing authorization from Chile's National ...

Bio & Pharma Daewoong’s Nabota expands into Germany, Austria

South Korean drugmaker Daewoong Pharmaceutical Co. said on Tuesday it had launched its botulinum toxin product Nabota in Germany and Austria through i...

Bio & Pharma Daewoong Pharma's Fexuclue safe to use with aspirin: Clinical trials

Daewoong Pharmaceutical Co., a leading South Korean pharmaceutical company, has announced the successful completion of phase 1 clinical trials for...

Bio & Pharma Dubai delegation conducts due diligence on Medytox's plant in Korea

South Korea's biopharmaceutical firm Medytox Inc. said on Monday that a high-level delegation led by Dubai Science Park (DSP) under Dubai's state-ow...

Bio & Pharma Jetema applies to test its botulinum toxin in US from July

South Korea's bio-esthetic pharmaceutical company Jetema Co. will hold clinical trials in the US to advance to the American market, the world's bigg...

Bio & Pharma Korea's Daewoong to export diabetes drug Envlo to Brazil, Mexico

South Korea’s Daewoong Pharmaceutical Co. said on Feb. 24 it is set to embark on global sales of Envlo, a new drug for diabetes, by exportin...

Bio & Pharma US calls on 2 S.Korean pharmaceutical companies for swift end to legal battle

Following its lawsuit against Daewoong Pharmaceutical, South Korea's Medytox Inc. is waging an all-out legal war against domestic counterpart Hugel ...

Bio & Pharma Korean court rules Daewoong poached Medytox’s botox strain

A South Korean court on Friday ruled in favor of Medytox Inc. in a civil lawsuit against its crosstown rival Daewoong Pharmaceutical Co. over the so...